Non-GAAP adjusted EBITDA loss narrowed 56% to $3.2 million; cash and cash equivalents increased 17% to $30 million, including $6.5 million from the at-the-market program.
Biodesix maintained FY 2026 revenue guidance of $108 million to $114 million, targeting roughly 80% gross margin and continued adjusted EBITDA improvement.
Q2 results and margin improvement
Biodesix posted Q2 2026 revenue of $26.9 million, up 34% year over year; GAAP net loss narrowed 37% to $7.3 million.
Gross margin improved 2 percentage points to 82%, as diagnostic testing volumes climbed 38% to 20,900 on expanded payer coverage.
Diagnostic Testing revenue rose 42% to $25.4 million, while Development Services revenue fell to from on project timing.
BDSX•
